antiviral

…Laboratory diagnosis can be achieved through elec­ ining the potential antiviral roles and healing properties of tron microscopy, PCR based on the amplification of B2L4 the pain-relief formulation in naturally infected…

ia/MultiSolfen® ; M-S; Dechra, UK). Serum amyloid A (SAA), a marker of systemic This article is an open access article distributed under the terms and inflammation, was measured in both experimentally and naturally infected lambs allocated conditions of the Creative Commons to treated and untreated groups. Samples were collected prior to (T0) and at 2 (T2), 7 (T7) Attribution (CC BY) license. and 14 (T14) days post-treatment in experimentally infected lambs and at T0, 10 (T10) and Animals 2026, 16, 17 https://doi.org/10.3390/ani16010017 Animals 2026, 16, 17 2 of 12 20 (T20) days post-treatment in naturally affected lambs. In the experimental infection, SAA concentrations were lower in the treated group than in controls at T7 and significantly lower at T14. In the natural outbreak, SAA concentrations significantly decreased over time in the treated group, with a consistent trend toward lower values than in controls. These findings indicate that this therapeutic formulation reduces systemic inflammatory responses in lambs affected by CE, supporting its use as an alternative to antibiotics. Keywords: orf virus; contagious ecthyma; lambs; local antiseptic/anaesthetic formulation; serum amyloid A 1. Introduction Contagious ecthyma (CE, Orf) is a highly contagious, globally distributed skin disease primarily affecting small ruminants, especially young animals in their first year of life [1]. The disease is a non-systemic, eruptive skin infection caused by the Orf virus (ORFV), a member of the family Poxviridae and genus Parapoxvirus [2]. Clinically, CE is characterised by papules, vesicles, pustules and proliferative scabby lesions, mainly of the muzzle and lip mucosae, often extending to the oral mucosa, nostrils, ears and eyelids and, less frequently, the feet, genitals

…2020;00:1–12. https://doi. Haines, H. G., Dickens, C. B., & Brigham, D. P. (1986). Antiviral org/10.1111/tbed.13923 pharmaceutical preparations and methods for their use. Patent US 4628063A

rrier effect, numbing the pain of lesions, rapidly reducing their infectivity, and hastening healing, potentially reducing the weight loss in affected individuals (Windsor et al., 2020). If made available for purchase and administration by farmers, this product could provide a viable alternative approach for managing FMD in Cameroon, other African countries and developing countries globally. This formulation offers numerous advantages over current therapies as it provides efficacious pain relief and more rapid healing of wounds and lesions (Windsor et al., 2016; Roberts and Windsor, 2019; Windsor et al., 2020). Further, with a pH of ˜2.7, and containing the antiseptic cetrimide, it potentially has viricidal impacts and anti-bacterial properties respectively, avoiding the need for other treatments, including antibiotics (Windsor et al, 2020). In November 2019, TS was provided to the Cameroon research team for trials during FMD outbreaks in cattle. This report describes a field trial in Cameroon aimed at evaluating the efficacy of this therapy for FMD lesion management, particularly for enhancing recovery and wound healing, comparing the clinical responses to the most commonly used and available antimicrobial therapy currently in use. If TS is proven to be as efficacious for FMD in this current study as it appeared to be on first use in Laos as described (Windsor et al., 2020), it is likely that the product could offer an important innovation for improving FMD lesion treatment, potentially globally, with reduced animal welfare burdens, risks of AMR issues and possibly, increased transboundary disease reporting and surveillance. MATERIALS AND METHODS Trial location and design This clinical trial was conducted between the 5th of November and the 5th of December 2019 in